One in eight U.S. adults uses GLP-1 drugs; Medicare now opens weight-loss access
Weight-loss medications have reached a milestone for millions of Americans. As of July 1, 2026, the Medicare GLP-1 Bridge Program allows beneficiaries to access weight-loss drugs through a pilot initiative. Previously, Medicare Part D coverage explicitly excluded medications associated with weight loss or gain unless they treated an underlying condition.
The new program operates as a short-term demonstration running through the end of 2027. It functions independently of standard Part D plans. Medicare manages the process centrally, handling prior authorization, claims, and payments to pharmacies. This structure allows eligible beneficiaries to bypass the typical plan-specific hurdles for these specific medications.
To qualify, a patient must meet specific body mass index (BMI) requirements. Those without other conditions need a BMI of 35 or higher. For patients with underlying health conditions, the threshold is 27. The program covers specific formulations of Wegovy, Foundayo, and the KwikPen version of Zepbound. Participants pay a flat $50 copay for each prescription.
Experts note that these medications are intended for long-term use. Dr. David Cummings of UW Medicine emphasizes that these drugs are often treated as permanent solutions for weight management, similar to maintenance medication for cholesterol or blood pressure. Patients should expect to consult their physicians first, as providers must submit the necessary documentation to the program’s central processor before a patient can fill a prescription at their pharmacy.
While this expansion increases access, there is a financial caveat. The $50 copays do not count toward a beneficiary’s standard Part D deductible or the $2,100 out-of-pocket limit. Beneficiaries should review their individual financial plans alongside this new access to understand the total impact on their healthcare budgets. The program aims to address the significant demand for these drugs, as current data indicates one in eight U.S. adults now takes a GLP-1 medication for weight management, diabetes, or heart health.